Multiple sclerosis and Injection site irritation

Summary:

Injection site irritation is found among people with Multiple sclerosis, especially for people who are female, 40-49 old.

The study analyzes which people have Injection site irritation with Multiple sclerosis. It is created by eHealthMe based on reports of 639 people who have Multiple sclerosis from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,085 drugs and 1,365 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.

What is Injection site irritation?

Injection site irritation is found to be associated with 452 drugs and 511 conditions by eHealthMe. Check the latest studies of Injection site irritation.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 22, 2026

639 people who have Multiple Sclerosis and Injection Site Irritation are studied.

Would you have Injection site irritation when you have Multiple sclerosis?

Gender of people who have Multiple sclerosis and experienced Injection site irritation *:

Click here to view

Age of people who have Multiple sclerosis and experienced Injection site irritation *:

Click here to view

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Injection site irritation?

- Check whether Injection site irritation is associated with a drug or a condition

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .

Related studies:

Treatments, associated drugs and conditions:

Multiple sclerosis (799,637 reports)
Injection site irritation (12,419 reports)

All the drugs that are associated with Injection site irritation:

Injection site irritation (452 drugs)

All the conditions that are associated with Injection site irritation:

Injection site irritation (511 conditions)

How the study uses the data?

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

The study is based on Injection site irritation and Multiple sclerosis, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.